COMMUNIQUÉS West-GlobeNewswire

Spectral AI to Participate in 2026 British Burn Association Annual Conference
11/06/2026
Company Will Showcase FDA-Cleared DeepView® System for Burn Indication DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) [...]
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
11/06/2026
License allows the Company to commence large-scale extraction of castanospermine from the seeds of Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency [...]
Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders
11/06/2026
Findings from 13 different studies analyzing 730 subjects to date in 2026 across multiple geographies underscore utility of OGM in key research areas including infertility, recurrent pregnancy loss, preimplantation [...]
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
11/06/2026
The clearance combines OraSure’s Colli-Pee™•Dx Urine Collection Kit for at-home sample collection with Roche’s cobas® molecular lab testing equipment BETHLEHEM, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- OraSure [...]
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
11/06/2026
16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) First patient randomized in the United Kingdom Clinical trial sites now actively enrolling in the United States, Australia, and the [...]
Announcing the 2026 Hall of Fame Philadelphia Titan 100 Honorees
11/06/2026
BERWYN, Pa., June 11, 2026 (GLOBE NEWSWIRE) -- Titan CEO and headline sponsor Cherry Bekaert are pleased to announce Dea Belazi, CEO and co-founder, AscellaHealth , a global partner delivering customizable solutions for [...]
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
11/06/2026
BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases [...]
What Science-Backed Subscription Health Programs Measure Differently
11/06/2026
The weight loss and weight management market was valued at $31.07 billion in 2025 A program can describe its results as clinically meaningful without specifying what was measured, how it was measured, or whether the [...]
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
11/06/2026
BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial-stage biotechnology company, today announced that [...]
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
11/06/2026
NEW YORK and TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Helus Pharma TM (Nasdaq: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists [...]
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
11/06/2026
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well Tolerated With [...]
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
11/06/2026
Data demonstrate favorable safety and tolerability profile, robust B - cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the [...]
Metabolic Health After 40: What Perimenopause and Menopause Mean for Weight Management
11/06/2026
Declining estrogen during perimenopause accelerates visceral fat accumulation and lean muscle loss, two outcomes that standard weight management programs are not designed to address together (Szeliga A, et al., 2026) [...]
Spinach® is the Number One Vape Brand in Canada
11/06/2026
Spinach® vapes, known for exceptional quality, bold flavor profiles and advanced hardware, continue to resonate with adult consumers across Canada TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: [...]
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
11/06/2026
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of Part 1 will assess [...]
Verano Completes 1-for-5 Reverse Stock Split, Advancing the Company’s Path Towards Prospective U.S. Stock Exchange Listing
11/06/2026
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that the 1-for-5 reverse stock split (“ [...]
Pharvaris Announces Annual General Meeting of Shareholders
11/06/2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living [...]
Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia
11/06/2026
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in [...]
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
11/06/2026
– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib with intensive [...]

Pages